The Source • April/May 2008 • Issue 101

Printer friendly

Lessons and Questions from the E2100 Avastin Breast Cancer Trial

by Robert Erwin The Food and Drug Administration (FDA) granted accelerated approval this past February to biotech company Genentech to market Avastin (bevacizumab) for the treatment of metastatic breast cancer. The FDA defines “accelerated approval” as “a provisional approval with a written commitment to complete… Read More

Putting Patients First: The Need for Better Standards at the FDA

by Barbara A. Brenner I have written frequently about the Food and Drug Administration for this column. It has never seemed more important than now to spell out in the clearest possible terms what breast cancer patients need from the FDA and why. The FDA’s… Read More

Healthy Job, Healthy Body A Profile of Women’s Action to Gain Economic Security

by Pauli Ojea Imagine a stable job that pays well, includes benefits, provides opportunities for education and training, and is safe and healthy for workers. (If this describes your own job, you’re better off than most people in the U.S. workforce.) Now imagine that at… Read More

Other Articles in this Issue